Higher FTX-6058 Doses Raise Hemoglobin in Healthy Adults in Trial

Higher FTX-6058 Doses Raise Hemoglobin in Healthy Adults in Trial

314424

Higher FTX-6058 Doses Raise Hemoglobin in Healthy Adults in Trial

Higher doses of FTX-6058, an investigational oral treatment for sickle cell disease (SCD), effectively raised hemoglobin messenger RNA (mRNA) levels above those found at lower doses in healthy volunteers participating in a Phase 1 trial, new data suggests. Increases in hemoglobin mRNA — the molecule cells use as a template to produce proteins — translated to similar increases in the number of red blood cells containing fetal hemoglobin, a form of hemoglobin produced during fetal…

You must be logged in to read/download the full post.